Amgen asks trade commission to block import of peg-EPO by Roche

New York, April 11 - Amgen said it has filed a complaint with the U.S. International Trade Commission asking it to investigate Roche's importation of pegylated recombinant human erythropoietin to the United States.

Amgen said it believes that importation of peg-EPO is unlawful because the compound and the method of its manufacture are covered by Amgen's patents.

Amgen is a Thousand Oaks, Calif., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.